Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials.
cognition
early clinical trial
prediction
prodromal Alzheimer's disease
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
05
05
2021
received:
30
07
2020
accepted:
24
06
2021
pubmed:
6
9
2021
medline:
9
4
2022
entrez:
5
9
2021
Statut:
ppublish
Résumé
Recent Food and Drug Administration guidance endorses cognitive assessment as a possible primary endpoint for early trials for Alzheimer's disease but emphasizes the need for certainty regarding the relationship with progression to dementia. We compared the validity of the 2-year change (Y0-Y2) of 11 markers of neuropsychological and functional abilities for the prediction of incident dementia over the following 3 years (Y2-Y5), in 860 subjects aged 70 years or older, who consulted for memory loss and were included in the "GuidAge" prevention trial. The Free and Cued Selective Reminding Test-Free Recall (FCSRT-FR) score showed the most predictive 2-year change (area under the curve = 0.72 95% confidence interval = 0.64;0.81). Changes in other subscores of the FCSRT, verbal fluencies tasks, and composite cognitive score were also significantly predictive. Conversely, 2-year change of Mini-Mental State Examination, Trail Making test (TMT)-A, TMT-B, Clinical Dementia Rating Sum of Boxes, and Instrumental Activities of Daily Living scores did not significantly predict occurrence of dementia. The FCSRT, the Fluency Task, and the composite cognitive score appear to be good cognitive markers of progression toward dementia in early prevention trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
676-687Informations de copyright
© 2021 the Alzheimer's Association.
Références
Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207-216.
Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer's dementia. Arch Gen Psychiatry. 2012;69:98-106.
Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64:492-498.
Golde TE. Disease modifying therapy for AD? J Neurochem. 2006;99:689-707.
Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111cm33.
Khan TK, Alkon DL. Alzheimer's disease cerebrospinal fluid and neuroimaging biomarkers: diagnostic accuracy and relationship to drug efficacy. J Alzheimers Dis. 2015;46:817-836.
US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry. 2018.
Dubois B. Interest of the new criteria for drug trials in AD. J Nutr Health Aging. 2009;13:356-357.
Harrison JK, Noel-Storr AH, Demeyere N, Reynish EL, Quinn TJ. Outcomes measures in a decade of dementia and mild cognitive impairment trials. Alzheimer's Res Ther. 2016;8:48.
Auriacombe S, Helmer C, Amieva H, Berr C, Dubois B, Dartigues JF. Validity of the free and cued selective reminding test in predicting dementia: the 3C study. Neurology. 2010;74:1760-1767.
Mura T, Proust-Lima C, Jacqmin-Gadda H, et al. Measuring cognitive change in subjects with prodromal Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2014;85:363-370.
Insel PS, Donohue MC, Mackin RS, et al. Cognitive and functional changes associated with Abeta pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016;48:172-181.
Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11:851-859.
Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer's disease in patients over 70 with a memory complaint. Neurology. 2006;67:S6-11.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
Lipman RS, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. Baltimore: Johns Hopkins University Press; 1976.
Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37-49.
Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900-903.
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
American Psychiatrique Association. Diagnostic and statistical manual of mental disorders. 4th ed. American Psychiatrique Association ed. Washington, DC: American Psychiatrique Association; 1994.
Van der linden M, Coyette F, Poitrenaud J, E GREMEM. L’épreuve de rappel libre/rappel indicé à 16 items (RL/RI - 16). In: Van der Linden M AS, Agniel A et les membres du GREMEM, editor. L’évaluation des troubles de la mémoire Présentation de quatre tests de mémoire épisodique (avec leur étalonnage). Marseille, France: Solal; 2004:25-47.
Reitan R. Validity of the Trail making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276.
Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. [Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level]. Acta Neurol Belg. 1990;90:207-217.
O'Bryant SE, Lacritz LH, Hall J, et al. Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol. 2010;67:746-749.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
Peres K, Helmer C, Amieva H, et al. Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study. J Am Geriatr Soc. 2008;56:37-44.
Coley N, Gallini A, Ousset PJ, Vellas B, Andrieu S. Evaluating the clinical relevance of a cognitive composite outcome measure: an analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. Alzheimer's Dement. 2016;12:1216-1225.
Burnham SC, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G. Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal Alzheimer's disease trials: an AIBL Study. J Alzheimers Dis. 2015;46:1079-1089.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 1994;4th ed. Washington, DC: American Psychiatric Association.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
Chiang CT, Hung H. Non-parametric estimation for time-dependent AUC. J Statis Plan Infer. 2010;140:1162-1174.
Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601-609.
Hung H, Chiang CT. Estimating and comparing timedependent areas under receiver operating characteristic curves for censored event times with competing risks. Statistics in medicine. Canad J Stat. 2010;38:8-26.
Coste J, Bouyer J, Job-Spira N. Construction of composite scales for risk assessment in epidemiology: an application to ectopic pregnancy. Am J Epidemiol. 1997;145:278-289.
Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med. 1997;16:1529-1542.
Jekel K, Damian M, Wattmo C, et al. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Res Ther. 2015;7:17.
Burton CL, Strauss E, Bunce D, Hunter MA, Hultsch DF. Functional abilities in older adults with mild cognitive impairment. Gerontology. 2009;55:570-581.
Jefferson AL, Byerly LK, Vanderhill S, et al. Characterization of activities of daily living in individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2008;16:375-383.
Di Stefano F, Epelbaum S, Coley N, et al. Prediction of Alzheimer's disease dementia: data from the GuidAge prevention trial. J Alzheimer's Dis. 2015;48:793-804.
Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology. 2007;69:1859-1867.
Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM. Relationship between amyloid-beta positivity and progression to mild cognitive impairment or dementia over 8 years in cognitively normal older adults. J Alzheimers Dis. 2018;65:1313-1325.
Insel PS, Mattsson N, Mackin RS, et al. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015;2:534-547.
Papp KV, Buckley R, Mormino E, et al. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimers Dement. 2020;16:552-560.
Rice ME, Harris GT. Comparing effect sizes in follow-up studies: rOC Area, Cohen's d, and r. Law Hum Behav. 2005;29:615-620.
Delgado C, Munoz-Neira C, Soto A, et al. Comparison of the psychometric properties of the “Word” and “Picture” versions of the free and cued selective reminding test in a spanish-speaking cohort of patients with mild Alzheimer's disease and cognitively healthy controls. Arch Clin Neuropsychol. 2016;31:165-175.
Slachevsky A, Barraza P, Hornberger M, et al. Neuroanatomical comparison of the “Word” and “Picture” versions of the free and cued selective reminding test in Alzheimer's disease. J Alzheimers Dis. 2018;61:589-600.
Arighi A, Carandini T, Mercurio M, et al. Word and picture version of the free and cued selective reminding test (FCSRT): is there any difference?. J Alzheimers Dis. 2018;61:47-52.
Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc. 2003;9:419-428.
Blasi S, Zehnder AE, Berres M, Taylor KI, Spiegel R, Monsch AU. Norms for change in episodic memory as a prerequisite for the diagnosis of mild cognitive impairment (MCI). Neuropsychology. 2009;23:189-200.